Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?

Thrombosis and Haemostasis

Volumn 103, Issue 3, 2010, Pages 481-483

  Eikelboom, John W ^a   Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; AR H 067637; AZD 0837; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; MORBIDITY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG TOXICITY; HUMANS; STROKE; THROMBIN;

EID: 77749252193     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-12-0828     Document Type: Editorial

References (9)

1. Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370: 604-618.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
3. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875.
4. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
5. Testa L, Bhindi R, Agostoni P, et al. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf 2007; 6: 397-406.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
7. Deinum J, Mattsson C, Inghardt T, et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost 2009; 101: 1051-1059.
8. Olsson SB, Rasmussen LH, Tveit A, et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010; 103: 604-612.
9. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009; 30: 2897-2907.